Supply Chain Intelligence

Immuneering Corporation Supply Chain

IMRX supply chain intelligence for Immuneering Corporation: verified suppliers, customers, debt relationships, acquisitions, and ownership data.

IMRX ·Last updated 2026-07-29 · Interactive map →

Data compiled by Redley Lamar · ChainSifter Intelligence

7Suppliers
0Customers
3Debt Items
20Related Chains

Immuneering Corporation Suppliers

TickerNameConfidenceEvidence
AVENTIS AVENTIS 92% The Company entered into the September 2025 Purchase Agreement with Aventis, a wholly-owned subsidiary of Sanofi, pursuant to which the Company agreed to sell securities to Aventis in the September 2…
LLY Eli Lilly and Company 92% Reciprocal relationship from LLY graph: Reciprocal relationship from IMRX graph: Reciprocal relationship from LLY graph: Reciprocal relationship from IMRX graph: Reciprocal relationship from LLY grap…
LLY Eli Lilly and Company 92% In August 2025, we announced a clinical supply agreement with Eli Lilly and Company for its second-generation KRAS G12C inhibitor, olomorasib (LY3537982), which intends to support the evaluation of a…
REGENERON-PHARMACEUTICALS REGENERON-PHARMACEUTICALS 92% In February 2025, we announced entry into a clinical supply agreement with Regeneron Pharmaceuticals for its anti-PD-1 therapy, Libtayo® (cemiplimab), which intends to support the evaluation of atebi…
SANOFI SANOFI 92% The Company entered into the September 2025 Purchase Agreement with Aventis, a wholly-owned subsidiary of Sanofi, pursuant to which the Company agreed to sell securities to Aventis in the September 2…
PIPER-SANDLER-CO PIPER-SANDLER-CO 90% On August 10, 2022, the Company entered into an Equity Distribution Agreement (the "2022 Sales Agreement") with Piper Sandler & Co (the "Sales Agent"), to sell shares of its common stock with aggrega…
OPPENHEIMER-CO-INC OPPENHEIMER-CO-INC 85% On September 26, 2025, we completed the September 2025 Offering, pursuant to which we issued and sold 18,959,914 shares of our common stock at an offering price of $9.23 per share, with Leerink Partn…

Immuneering Corporation Customers

No clients on recordNo downstream customers found in our database for Immuneering Corporation.

Immuneering Corporation Debt Obligations

InstrumentDescriptionConfidenceEvidence
IMRX-DEBT-10250 Warrants outstanding: 308308 90% xbrl warrant detail from xbrl 2021-12-31.
IMRX-DEBT Debt stack $3.7M 90% Market cache reports total debt of $3.7M.
IMRX-DEBT-10251 Xbrl Convertible 90% xbrl convertible detail from xbrl 2021-12-31.

Immuneering Corporation Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Immuneering Corporation.

Immuneering Corporation Ownership

HolderNameConfidenceEvidence
IMRX-OWNER-FMR-LLC FMR LLC 90% 13F overlay lists FMR LLC as top holder; 95 tracked holders.

Immuneering Corporation Extended Supply Chain Network

TickerNameChain IndexHopsRelationship Types
REGN Regeneron Pharmaceuticals, Inc. 100.00 2
SVA Sinovac Biotech Ltd. 100.00 2
BLRX BioLineRx Ltd. 100.00 2
ATOS Atossa Therapeutics, Inc. 100.00 2
CALC CalciMedica, Inc. 100.00 2
ANRO Alto Neuroscience, Inc. 100.00 2
WHWK Whitehawk Therapeutics, Inc. 100.00 2
BIOA BioAge Labs, Inc. 100.00 2
CTMX CytomX Therapeutics, Inc. 100.00 2
CBIO Crescent Biopharma, Inc. 100.00 2
ANL Adlai Nortye Ltd. 100.00 2
ALXO ALX Oncology Holdings Inc. 100.00 2
CCEP Coca-Cola Europacific Partners PLC 100.00 2
DSGN Design Therapeutics, Inc. 100.00 2
AZN AstraZeneca PLC 100.00 2
CYTOF Altamira Therapeutics Ltd. 100.00 2
DBVTF DBV TECHNOLOGIES 100.00 2
EDIT Editas Medicine, Inc. 100.00 2
CYTK Cytokinetics, Incorporated 100.00 2
GRDX GridAI Technologies Corp. 100.00 2
View IMRX supply chain intel →

Explore the full interactive supply chain map for Immuneering Corporation.

Open IMRX supply chain map →
ChainSifter · Guerilla Finance Terms Disclaimer ← Back to Map